50 results about "Tomoxetine" patented technology

Provided is an efficient method for the preparation of 3-aryloxy-3-arylpropylamines, their optical stereoisomers, and pharmaceutically acceptable salts thereof. The process allows for the isolation of 3-aryloxy-3-arylpropylamines in high yield and purity. The present invention further relates to a process for producing fluoxetine, tomoxetine, norfluoxetine, duloxetine, nisoxetine, and their optically enriched (R)- and (S)-enantiomers.

The invention discloses a class of chiral tridentate nitrogen phosphine ligand and its application in asymmetric hydrogenation and similar reactions. The tridentate nitrogen phosphine ligand disclosed in the present invention is the first chiral oxazoline-containing tridentate nitrogen phosphine ligand, and has been successfully applied to the hydrogenation reaction of ketones and imide salts and similar reactions with high efficiency and high selectivity . Compared with other ligands, the synthetic route is simple, the yield is high, and it is more environmentally friendly. In addition, the metal complexes of this type of ligand not only show better selectivity in asymmetric hydrogenation reactions, but also show higher conversion numbers . The iridium complex of the chiral tridentate nitrogen phosphine ligand of the present invention has successfully asymmetrically reduced β-ketone lipids to β-alcohol lipids (raw materials for the synthesis of molecular drugs duloxetine and atomoxetine), and α ‑Hydroxyacetophenone asymmetrically hydrogenates α‑hydroxyphenylethanol, and asymmetrically hydrogenates acetophenone to phenylethyl alcohol, which is of great significance for the production of the pharmaceutical industry.

The present invention provides enantiomerically pure (R)-(-)-tomoxetine (S)-(+)-mandelate and atomoxetine HCI. The present invention further provides enantiomerically pure (R)-(-)-tomoxetine (S)-(+)-mandelate prepared from racemic 5 tomoxetine. The present invention also provides enantiomerically pure atomoxetine HCI prepared from (R)-(-)-tomoxetine (S)-(+)-mandelate.

Various embodiments disclosed herein include methods of modulating the function of Zinc Activated Cation Channel (ZACN) in a subject comprising: administering to the subject a pharmaceutically effective dosage of ATP, a purinergic compound, red or blue dye, heparin or heparin analog, desipramine, reboxetine, and / or tomoxetine; and modulating the function of ZACN in the subject. Various embodiments disclosed herein also include methods of treating a disease in a subject comprising: administering to the subject a pharmaceutically effective dosage of a compound capable of modulating the function of the Zinc Activated Cation Channel (ZACN), and treating the disease.